Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company pioneering therapies for severe rare disorders through advanced modalities including antibodies and engineered proteins. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific progress and operational developments.
Access timely reports on clinical trial milestones, regulatory submissions, and strategic collaborations. Our curated collection features verified press releases, financial disclosures, and analysis of RLYB's innovative pipeline targeting conditions like fetal/neonatal alloimmune thrombocytopenia.
Key updates include progress on therapeutic candidates, partnership announcements with research institutions, and financial performance summaries. The resource is particularly valuable for tracking Rallybio's unique approach combining validated biological mechanisms with novel treatment strategies.
Bookmark this page for streamlined access to Rallybio's latest advancements in rare disease research. Check regularly for authoritative reporting on clinical developments and corporate announcements from this innovative biopharma leader.
Rallybio (Nasdaq: RLYB) reported first quarter 2024 financial results, highlighting $94.2 million in cash as of March 31, 2024. The company is on track to start a Phase 2 trial for RLYB212 in pregnant women at higher risk of FNAIT in the second half of 2024. Rallybio also announced a collaboration with Johnson & Johnson, received an equity investment of $6.6 million, and is prioritizing its portfolio with a focus on RLYB212 and RLYB116. The company continues to progress in its clinical programs and expects to share additional data in the second half of 2024.
Rallybio (Nasdaq: RLYB) will present at the 2024 Citizens JMP Life Sciences Conference. Steve Uden, M.D., CEO, will participate in a fireside chat on May 14, 2024, at 11:30 a.m. ET in New York. The event will be live webcasted on Rallybio's website.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
